MarketCap
Facebook
X
TelegramAnnual report 2025
added 04-11-2026
China SXT Pharmaceuticals Total Liabilities 2011-2026 | SXTC
Annual Total Liabilities China SXT Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.22 M | 9.2 M | 14.9 M | 17.1 M | 18.6 M | 12.3 M | 6.36 M | 4.37 M | 3.58 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 M | 3.58 M | 10.3 M |
Quarterly Total Liabilities China SXT Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 17.1 M | - | 8.88 M | - | 18.6 M | - | 5.52 M | - | 12.3 M | - | 11.6 M | - | 6.36 M | - | - | - | 4.37 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 18.6 M | 4.37 M | 10.6 M |
Total Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
1.98 B | - | 2.43 % | $ 254 M |  Germany |
 |
Celldex Therapeutics
CLDX
|
55.8 M | $ 34.55 | 2.04 % | $ 2.29 B |  USA |
 |
Alterity Therapeutics Limited
ATHE
|
5.89 M | $ 4.47 | 12.59 % | $ 10.8 B |  Australia |
 |
Adverum Biotechnologies
ADVM
|
109 M | - | - | $ 86.2 M | USA |
 |
Akouos
AKUS
|
45.1 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
707 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
42.9 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
6.45 B | - | - | $ 40.3 B | USA |
 |
Genfit SA
GNFT
|
215 M | - | 2.54 % | $ 160 B |  France |
 |
Biophytis SA
BPTS
|
20.4 M | - | -13.47 % | $ 169 M | France |
 |
Akari Therapeutics, Plc
AKTX
|
19.6 M | $ 5.8 | 13.28 % | $ 391 B |  Britain |
 |
Aligos Therapeutics
ALGS
|
35 M | $ 6.68 | -12.79 % | $ 66 M | USA |
 |
Allakos
ALLK
|
74.8 M | - | - | $ 28.6 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
4.18 B | $ 309.66 | -3.27 % | $ 40.6 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
8.16 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
6.77 M | - | -18.52 % | $ 27.3 M | Britain |
 |
Applied Molecular Transport
AMTI
|
46.6 M | - | - | $ 10.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
840 M | $ 22.88 | 4.91 % | $ 1.07 B | USA |
 |
Applied Therapeutics
APLT
|
72 M | - | - | $ 8.42 M | USA |
 |
BioNTech SE
BNTX
|
2.76 B | $ 102.92 | 0.78 % | $ 27.2 B | Germany |
 |
Aptinyx
APTX
|
28.4 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
51.5 M | - | -13.39 % | $ 1.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
1.1 B | - | - | - |  Russia |
 |
Advaxis
ADXS
|
7.89 M | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
3.45 M | $ 3.04 | -1.3 % | $ 5 M |  Israel |
 |
Aeterna Zentaris
AEZS
|
17.6 M | - | 5.93 % | $ 314 M |  Canada |
 |
AgeX Therapeutics
AGE
|
6.99 M | - | -10.17 % | $ 12.2 K | USA |
 |
BioXcel Therapeutics
BTAI
|
140 M | $ 1.15 | 7.48 % | $ 14 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
62.5 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
344 M | $ 1.41 | 4.07 % | $ 363 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.43 M | - | - | $ 7.46 M | Israel |
 |
Applied Genetic Technologies Corporation
AGTC
|
37.2 M | - | - | $ 26.5 M | USA |
 |
Aquestive Therapeutics
AQST
|
194 M | $ 4.32 | 1.41 % | $ 462 M | USA |
 |
AstraZeneca PLC
AZN
|
65.4 B | - | - | $ 96.9 B | Britain |
 |
Arcutis Biotherapeutics
ARQT
|
243 M | $ 24.53 | 1.41 % | $ 3.12 B | USA |
 |
Burford Capital Limited
BUR
|
1.45 B | $ 4.96 | 6.1 % | $ 792 M | Britain |
 |
AIkido Pharma
AIKI
|
43.5 M | - | 1.93 % | $ 17.4 M | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
137 M | - | -4.8 % | $ 255 M | USA |
 |
Cabaletta Bio
CABA
|
53 M | $ 3.44 | -2.27 % | $ 346 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
411 M | $ 1.6 | -0.62 % | $ 426 M | Britain |
 |
Aptose Biosciences
APTO
|
37.2 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
BeiGene, Ltd.
BGNE
|
3.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
bluebird bio
BLUE
|
425 M | - | - | $ 546 M | USA |
 |
Citius Pharmaceuticals
CTXR
|
42.5 M | $ 0.86 | 0.39 % | $ 5.79 M | USA |
 |
Akero Therapeutics
AKRO
|
75.8 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
470 M | - | - | $ 867 M | Germany |
 |
Cidara Therapeutics
CDTX
|
51.5 M | - | - | $ 1.41 B | USA |
 |
CymaBay Therapeutics
CBAY
|
142 M | - | - | $ 3.45 B | USA |